Welcome!

News Feed Item

EpiCast Report: Overweight and Obesity - Epidemiology Forecast to 2022

LONDON, March 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

EpiCast Report: Overweight and Obesity - Epidemiology Forecast to 2022


EpiCast Report: Overweight and Obesity - Epidemiology Forecast to 2022

Summary

Overweight and obesity are characterized by abnormal or excessive fat accumulation in the body, which can increase the likelihood of developing type 2 diabetes and cardiovascular diseases. Obesity is an escalating public health problem with an increasing worldwide prevalence and has become a well-known threat to public health. As obesity is a complex condition associated with a wide range of lifestyle, genetic, social, cultural, and environmental factors, its prevalence may vary across countries, depending on the variations in these contributing factors.

GlobalData's epidemiological analysis forecasts that prevalent cases of overweight in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will increase from 250.05 million in 2012 to 271.86 million cases in 2022 at an annual growth rate (AGR) of 0.86%. Approximately 57% of the 250.05 million prevalent cases of overweight adults in the 9MM in 2012 were in men. GlobalData epidemiologists forecast that there were 167.39 million prevalent cases of obesity in the 9MM in 2012, which will increase to 213.34 million cases in 2022, increasing at an AGR of 2.75%. Approximately 52% of the 167.39 million prevalent cases of obese adults in the 9MM in 2012 were in women.

According to GlobalData's forecast, the prevalent cases of both overweight and obesity will increase dramatically over the next decade, with the number of obese adults increasing by an alarming 27.50%. Overweight and obesity have reached pandemic proportions; however, GlobalData epidemiologists believe that with the alarming increase in the prevalence of both overweight and obesity, the morbidity and mortality associated with the disease will continue to increase dramatically as well.

Scope

- The Overweight and Obesity EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of overweight and obesity in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada). It includes a 10-year epidemiology forecast of the prevalent cases of overweight, obesity, obesity class I, obesity class II, and obesity class III segmented by sex and age. In addition, the report includes a 10-year forecast of the prevalent cases of obesity-associated comorbidities, including diagnosed diabetes, diagnosed hypertension, and dyslipidemia, among adults with overweight/obesity in some of these markets.
- The overweight and obesity epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global overweight and obesity market.
- Quantify patient populations in the global overweight and obesity market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for overweight and obesity therapeutics in each of the markets covered.
- Identify the number of obesity class I, obesity class II, and obesity class III prevalent cases.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Epidemiology 12

3.1 Disease Overview 12
3.2 Risk Factors and Comorbidities 13
3.2.1 Family history is a strong predictor of obesity 13
3.2.2 Physical inactivity is an independent predictor of obesity 14
3.2.3 Excessive caloric intake doubles the risk for obesity 15
3.2.4 Hypertension is as high as 42% in obese adults 16
3.2.5 Dyslipidemia and type 2 diabetes are common comorbidities in obese patients 17
3.3 Global Trends 19
3.3.1 US 20
3.3.2 5EU 22
3.3.3 Japan 28
3.3.4 Brazil 29
3.3.5 Canada 31
3.4 Forecast Methodology 32
3.4.1 Sources Used 39
3.4.2 Forecast Assumptions and Methods: Prevalent Cases of Overweight, Obesity, Obesity by Class, and Comorbidities 46
3.4.3 Sources Not Used 63
3.5 Epidemiology Forecast of Overweight (2012–2022) 63
3.5.1 Prevalent Cases of Overweight 63
3.5.2 Age-Specific Prevalent Cases of Overweight 65
3.5.3 Sex-Specific Prevalent Cases of Overweight 67
3.5.4 Age-Standardized Prevalence of Overweight 70
3.6 Epidemiology Forecast of Obesity (2012–2022) 71
3.6.1 Prevalent Cases of Obesity 71
3.6.2 Age-Specific Prevalent Cases of Obesity 73

3.6.3 Sex-Specific Prevalent Cases of Obesity 75
3.6.4 Age-Standardized Prevalence of Obesity 76
3.7 Epidemiology Forecast of Obesity Class I (2012–2022) 77
3.7.1 Prevalent Cases of Obesity Class I 77
3.7.2 Age-Specific Prevalent Cases of Obesity Class I 79
3.7.3 Sex-Specific Prevalent Cases of Obesity Class I 81
3.7.4 Age-Standardized Prevalence of Obesity Class I 83
3.8 Epidemiology Forecast of Obesity Class II (2012–2022) 85
3.8.1 Prevalent Cases of Obesity Class II 85
3.8.2 Age-Specific Prevalent Cases of Obesity Class II 87
3.8.3 Sex-Specific Prevalent Cases of Obesity Class II 89
3.8.4 Age-Standardized Prevalence of Obesity Class II 91
3.9 Epidemiology Forecast of Obesity Class III (2012–2022) 93
3.9.1 Prevalent Cases of Obesity Class III 93
3.9.2 Age-Specific Prevalent Cases of Obesity Class III 95
3.9.3 Sex-Specific Prevalent Cases of Obesity Class III 97
3.9.4 Age-Standardized Prevalence of Obesity Class III 99
3.10 Epidemiology Forecast of Comorbidities among Adults with Overweight/Obesity (2012 and 2022) 101
3.10.1 Prevalent Cases of Diagnosed Diabetes among Adults with Overweight/Obesity 101
3.10.2 Prevalent Cases of Diagnosed Hypertension in Adults with Overweight/Obesity 104
3.10.3 Prevalent Cases of Dyslipidemia among Adults with Overweight/Obesity 106
3.11 Discussion 109
3.11.1 Conclusions on Epidemiological Trends 109
3.11.2 Limitations of the Analysis 110

3.11.3 Strengths of the Analysis 111
4 Appendix 112
4.1 Bibliography 112
4.2 About the Authors 118
4.2.1 Epidemiologists 118
4.2.2 Reviewers 118
4.2.3 Global Director of Epidemiology and Health Policy 119
4.2.4 Global Head of Healthcare 120
4.3 About GlobalData 121
4.4 About EpiCast 121
4.5 Disclaimer 121

1.1 List of Tables

Table 1: The WHO Classification System of Adult Overweight and Obesity According to BMI 12
Table 2: Risk Factors and Comorbidities of Obesity 13
Table 3: 9MM, Age-Adjusted and Crude Prevalence (%) of Obesity, by Sex, Ages ?20 Years, 2008 20
Table 4: JASSO and WHO Classifications of Obesity 28
Table 5: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Overweight 33
Table 6: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Obesity 34
Table 7: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Obesity Class I, Class II, and Class III 36
Table 8: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Comorbidities in Overweight/Obese 38
Table 9: 9MM, Prevalent Cases of Overweight, Ages ?18 Years, Both Sexes, N (Millions), 2012–2022 64
Table 10: 9MM, Prevalent Cases of Overweight, By Age, Both Sexes, N (Millions), Row (%), 2012 66
Table 11: 9MM, Prevalent Cases of Overweight, Ages ?18 Years, By Sex, N (Millions), Row (%), 2012 68

Table 12: 9MM, Prevalent Cases of Obesity, Ages ?18 Years, Both Sexes, N (Millions), 2012–2022 72
Table 13: 9MM, Prevalent Cases of Obesity, By Age, Both Sexes, N (Millions), Row (%), 2012 74
Table 14: 9MM, Prevalent Cases of Obesity, Ages ?18 Years, by Sex, N (Millions), Row (%), 2012 75
Table 15: 9MM, Prevalent Cases of Obesity Class I, Ages ?18 Years, Both Sexes, N (Millions), 2012–2022 78
Table 16: 9MM, Prevalent Cases of Obesity Class I, by Age, Both Sexes, N (Millions), Row (%), 2012 80
Table 17: 9MM, Prevalent Cases of Obesity Class I, Ages ?18 Years, By Sex, N (Millions), Row (%), 2012 82
Table 18: 9MM, Prevalent Cases of Obesity Class II, Ages ?18 Years, Both Sexes, N (Millions), 2012–2022 86

Table 19: 9MM, Prevalent Cases of Obesity Class II, By Age, Both Sexes, N (Millions), Row (%), 2012 88
Table 20: 9MM, Prevalent Cases of Obesity Class II, Ages ?18 Years, By Sex, N (Millions), Row (%), 2012 90
Table 21: 9MM, Prevalent Cases of Obesity Class III, Ages ?18 Years, Both Sexes, N (Millions), 2012–2022 94
Table 22: 9MM, Prevalent Cases of Obesity Class III, By Age, Both Sexes, N (Millions), Row (%), 2012 96
Table 23: 9MM, Prevalent Cases of Obesity Class III, Ages ?18 Years, By Sex, N (Millions), Row (%), 2012 98
Table 24: 5MM*, Prevalent Cases of Diagnosed Diabetes among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 and 2022 102
Table 25: 6MM*, Prevalent Cases of Diagnosed Hypertension among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 and 2022 105
Table 26: 4MM, Prevalent Cases of Dyslipidemia* among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 and 2022 107

1.2 List of Figures

Figure 1: US, Overweight and Obesity Age-Adjusted Prevalence (%), Ages 20–74 Years, Men, 1960–2010 21
Figure 2: US, Overweight and Obesity Age-Adjusted Prevalence (%), Ages 20–74 Years, Women, 1960–2010 21
Figure 3: France, Overweight and Obesity Prevalence (%), Ages ?15 Years, Men, 1997–2006 23
Figure 4: France, Overweight and Obesity Prevalence (%), Ages ?15 Years, Women, 1997–2006 23
Figure 5: Italy, Overweight and Obesity Prevalence (%), Ages ?18, Men, 1983–2010 25
Figure 6: Italy, Overweight and Obesity Prevalence (%), Ages ?18, Men, 1983–2010 25
Figure 7: UK, Overweight and Obesity Prevalence (%), Ages ?16 Years, Men, 1993–2011 27
Figure 8: UK, Overweight and Obesity Prevalence (%), Ages ?16 Years, Women, 1993–2011 27
Figure 9: Japan, Obesity Prevalence (%), Ages ?20 Years, By Sex, 1976–2006 29
Figure 10: Brazil, Overweight and Obesity Prevalence (%), Ages ?20 Years, Men, 1975–2003 30
Figure 11: Brazil, Overweight and Obesity Prevalence (%), Ages ?20 Years, Women, 1975–2003 30
Figure 12: Canada, Obesity Prevalence (%), Ages ?18 Years, Both Sexes, 1978–2008 32
Figure 13: 9MM, Prevalent Cases of Overweight, Ages ?18 Years, Both Sexes, N (Millions), 2012–2022 65
Figure 14: 9MM, Prevalent Cases of Overweight, by Age, Both Sexes, N (Millions), 2012 67
Figure 15: 9MM, Prevalent Cases of Overweight, Ages ?18 Years, by Sex, N (Millions), 2012 69
Figure 16: 9MM, Overweight Age-Standardized Prevalence (%), Ages ?18 Years, By Sex, 2012 71
Figure 17: 9MM, Prevalent Cases of Obesity, Ages ?18 Years, Both Sexes, N (Millions), 2012–2022 73

Figure 18: 9MM, Prevalent Cases of Obesity, By Age, Both Sexes, N (Millions), 2012 74
Figure 19: 9MM, Prevalent Cases of Obesity, Ages ?18 Years, by Sex, N (Millions), 2012 76
Figure 20: 9MM, Obesity Age-Standardized Prevalence (%), Ages ?18 Years, By Sex, 2012 77
Figure 21: 9MM*, Prevalent Cases of Obesity Class I, Ages ?18 Years, Both Sexes, N (Millions), 2012–2022 79
Figure 22: 9MM*, Prevalent Cases of Obesity Class I, By Age, Both Sexes, N (Millions), 2012 81
Figure 23: 9MM*, Prevalent Cases of Obesity Class I, Ages ?18 Years, by Sex, N (Millions), 2012 83
Figure 24: 9MM*, Obesity Class I Age-Standardized Prevalence (%), Ages ?18 Years, by Sex, 2012 84
Figure 25: 9MM*, Prevalent Cases of Obesity Class II, Ages ?18 Years, Both Sexes, N (Millions), 2012–2022 87
Figure 26: 9MM*, Prevalent Cases of Obesity Class II, By Age, Both Sexes, N (Millions), 2012 89
Figure 27: 9MM*, Prevalent Cases of Obesity Class II, Ages ?18 Years, by Sex, N (Millions), 2012 91
Figure 28: 9MM*, Age-Standardized Prevalence (%) of Obesity Class II, Ages ?18 Years, By Sex, 2012 92
Figure 29: 9MM*, Prevalent Cases of Obesity Class III, Ages ?18 Years, Both Sexes, N (Millions), 2012–2022 95
Figure 30: 9MM*, Prevalent Cases of Obesity Class III, By Age, Both Sexes, N (Millions), 2012 97
Figure 31: 9MM*, Prevalent Cases of Obesity Class III, Ages ?18 Years, By Sex, N (Millions), 2012 99
Figure 32: 9MM*, Obesity Class III Age-Standardized Prevalence (%), Ages ?18 Years, By Sex, 2012 100
Figure 33: 5MM*, Prevalent Cases of Diagnosed Diabetes among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 103
Figure 34: 6MM*, Prevalent Cases of Diagnosed Hypertension among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 106
Figure 35: 4MM*, Prevalent Cases of Dyslipidemia** among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 108

Read the full report:
EpiCast Report: Overweight and Obesity - Epidemiology Forecast to 2022
http://www.reportbuyer.com/pharma_healthcare/diseases/epicast_report_overweight_obesity_epidemiology_forecast_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com  
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Today most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes significant work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reducti...
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
Real IoT production deployments running at scale are collecting sensor data from hundreds / thousands / millions of devices. The goal is to take business-critical actions on the real-time data and find insights from stored datasets. In his session at @ThingsExpo, John Walicki, Watson IoT Developer Advocate at IBM Cloud, will provide a fast-paced developer journey that follows the IoT sensor data from generation, to edge gateway, to edge analytics, to encryption, to the IBM Bluemix cloud, to Wa...
With the rise of DevOps, containers are at the brink of becoming a pervasive technology in Enterprise IT to accelerate application delivery for the business. When it comes to adopting containers in the enterprise, security is the highest adoption barrier. Is your organization ready to address the security risks with containers for your DevOps environment? In his session at @DevOpsSummit at 21st Cloud Expo, Chris Van Tuin, Chief Technologist, NA West at Red Hat, will discuss: The top security r...
SYS-CON Events announced today that Fusic will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Fusic Co. provides mocks as virtual IoT devices. You can customize mocks, and get any amount of data at any time in your test. For more information, visit https://fusic.co.jp/english/.
The “Digital Era” is forcing us to engage with new methods to build, operate and maintain applications. This transformation also implies an evolution to more and more intelligent applications to better engage with the customers, while creating significant market differentiators. In both cases, the cloud has become a key enabler to embrace this digital revolution. So, moving to the cloud is no longer the question; the new questions are HOW and WHEN. To make this equation even more complex, most ...
"NetApp's vision is how we help organizations manage data - delivering the right data in the right place, in the right time, to the people who need it, and doing it agnostic to what the platform is," explained Josh Atwell, Developer Advocate for NetApp, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
IBM helps FinTechs and financial services companies build and monetize cognitive-enabled financial services apps quickly and at scale. Hosted on IBM Bluemix, IBM’s platform builds in customer insights, regulatory compliance analytics and security to help reduce development time and testing. In his session at 21st Cloud Expo, Lennart Frantzell, a Developer Advocate with IBM, will discuss how these tools simplify the time-consuming tasks of selection, mapping and data integration, allowing devel...
Today traditional IT approaches leverage well-architected compute/networking domains to control what applications can access what data, and how. DevOps includes rapid application development/deployment leveraging concepts like containerization, third-party sourced applications and databases. Such applications need access to production data for its test and iteration cycles. Data Security? That sounds like a roadblock to DevOps vs. protecting the crown jewels to those in IT.
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo Silicon Valley which will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. "DevOps is at the intersection of technology and business-optimizing tools, organizations and processes to bring measurable improvements in productivity and profitability," said Aruna Ravichandran, vice president, DevOps product and solutions marketing...
SYS-CON Events announced today that B2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. B2Cloud specializes in IoT devices for preventive and predictive maintenance in any kind of equipment retrieving data like Energy consumption, working time, temperature, humidity, pressure, etc.
Many organizations adopt DevOps to reduce cycle times and deliver software faster; some take on DevOps to drive higher quality and better end-user experience; others look to DevOps for a clearer line-of-sight to customers to drive better business impacts. In truth, these three foundations go together. In this power panel at @DevOpsSummit 21st Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, industry experts will discuss how leading organizations build application success from all...
SYS-CON Events announced today that NetApp has been named “Bronze Sponsor” of SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. NetApp is the data authority for hybrid cloud. NetApp provides a full range of hybrid cloud data services that simplify management of applications and data across cloud and on-premises environments to accelerate digital transformation. Together with their partners, NetApp em...
Elon Musk is among the notable industry figures who worries about the power of AI to destroy rather than help society. Mark Zuckerberg, on the other hand, embraces all that is going on. AI is most powerful when deployed across the vast networks being built for Internets of Things in the manufacturing, transportation and logistics, retail, healthcare, government and other sectors. Is AI transforming IoT for the good or the bad? Do we need to worry about its potential destructive power? Or will we...